Department of Pharmacology and Toxicology, The Brody School of Medicine at East Carolina University, Greenville, NC 27834, United States.
Biochem Pharmacol. 2010 Aug 15;80(4):522-32. doi: 10.1016/j.bcp.2010.05.005. Epub 2010 May 15.
Few studies have compared the nature of tolerance that develops following chronic opioid treatment with that which develops after chronic cannabinoid exposure in the same tissue and species. The degree and character of tolerance induced by 7 twice daily injections of morphine or 5 daily injections of the cannabinoid receptor agonist, WIN-55,212-2, was examined by comparing the ability of DAMGO, 2-chloroadenosine (CADO) and WIN-55,212-2 to inhibit neurogenic contractions of the longitudinal muscle/myenteric plexus preparation (LM/MP) and the ability of nicotine to elicit contractions in the LM/MP. Chronic morphine treatment resulted in subsensitivity to all inhibitory agonists (rightward shift in IC(50) values of 4-5-fold) and an increased responsiveness to the excitatory effect of nicotine while chronic WIN-55,212-2 exposure resulted in subsensitivity only to WIN-55,212-2 and a reduction in maximum response to both WIN-55,212-2 and DAMGO but no change in responsiveness to CADO. Chronic WIN-55,212-2 treatment significantly reduced CB(1) but not MOR receptor protein abundance while chronic morphine treatment did not change either. Assessment of the distribution of MOR and CB(1) receptors in myenteric neurons revealed distinct individual receptor expression as well as co-localization which was unaffected by either cannabinoid or opioid treatment. Thus, in contrast to the heterologous tolerance that develops after opioid treatment, tolerance in the LM/MP following chronic in vivo WIN-55,212-2 exposure appears to be homologous in character and is accompanied by a selective decrease in CB(1) receptor protein abundance. The data suggest that the cellular basis of tolerance differs between the two systems.
很少有研究比较慢性阿片类药物治疗后和同一组织及物种中慢性大麻素暴露后产生的耐受性的性质。通过比较吗啡 7 次每日 2 次注射或大麻素受体激动剂 WIN-55,212-2 5 次每日注射后引起的 DAMGO、2-氯腺苷(CADO)和 WIN-55,212-2 抑制纵向肌/肌间神经丛制剂(LM/MP)的神经源性收缩的能力,以及尼古丁引起 LM/MP 收缩的能力,来检查对耐受的诱导程度和特性。慢性吗啡处理导致对所有抑制性激动剂的敏感性降低(IC50 值向右移位 4-5 倍),并增加对尼古丁兴奋作用的反应性,而慢性 WIN-55,212-2 暴露仅导致对 WIN-55,212-2 的敏感性降低,并减少对 WIN-55,212-2 和 DAMGO 的最大反应,但对 CADO 的反应性没有变化。慢性 WIN-55,212-2 处理显著降低了 CB1 但不降低 MOR 受体蛋白丰度,而慢性吗啡处理没有改变这两种受体。对肌间神经元中 MOR 和 CB1 受体的分布进行评估表明,存在独特的个体受体表达以及共存,这两种受体都不受大麻素或阿片类药物处理的影响。因此,与阿片类药物处理后产生的异源耐受相反,在 LM/MP 中,慢性体内 WIN-55,212-2 暴露后产生的耐受在性质上似乎是同源的,并且伴随着 CB1 受体蛋白丰度的选择性降低。这些数据表明,这两个系统的耐受的细胞基础不同。